Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs
Investors want clearer targets as trial setbacks, patent expiries and rising competition leave the company’s next growth drivers uncertain.
- Novo faces intense pressure as rival Lilly's Zepbound treatment is expected to outpace Wegovy by more than $7 billion this year, leaving investors demanding clarity on the European firm's roadmap amid semaglutide patent expiries.
- After trial setbacks including the failure of CagriSema, Novo shares plunged more than 70% from their peak, prompting the company to raise its sales and operating profit growth targets to between zero and minus 6%.
- Sydbank analyst Soren Lontoft Hansen said it will be a "very tough task" to convince the market of Novo's strength given price pressure and semaglutide patent expiry at the beginning of the next decade.
- Union Investment portfolio manager Markus Manns argued Novo should diversify into other therapeutic areas, stating, "They should work harder in building a third leg," as internal research alone cannot bridge the revenue gap.
- Investors point to European rival AstraZeneca, which forecast $80 billion in annual revenue by 2030, as a model, while analysts warn that without acquisitions, Novo lacks power to compete in the $100 billion weight-loss market.
6 Articles
6 Articles
Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs
Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is crucial for Novo to navigate patent challenges and competitive threats with a transparent and strategic…
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs
Wegovy-maker Novo Nordisk's CEO Mike Doustdar will face pressure on Monday to set out his strategy for competing with US rival Eli Lilly and how he plans to boost the company's growth beyond the blockbuster weight-loss drug.
The Semaglutide Cliff vs. a 10x Multiple: Is Novo Nordisk (NVO) a Value Trap or a Bargain?
Morgan Stanley has cut Novo Nordisk A/S (NYSE:NVO) to Underweight on September 11, 2026. Semaglutide, the underlying molecule for Wegovy and Ozempic, generates roughly 75% of 2026 revenue. Morgan Stanley models that it will still represent 59% of total sales when its patent protection expires in…
Novo Nordisk Stock at $43.24 Faces a Semaglutide Strategy Test
London, September 20, 2026, 14:10 (BST) Novo’s Capital Markets Day starts Monday at 09:00 BST.NVO closed Friday at $43.24, up 0.12% on 10.36 million shares.Morgan Stanley estimates semaglutide will supply 75% of 2026 sales. Novo Nordisk A/S (NYSE:NVO; CPH:NOVO-B) will open its Capital Markets Day in London on Monday. Its U.S. shares closed Friday at…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
